# ViewPoint Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viewpoint-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.viewpointtherapeutics.com
- Total disclosed funding: $39M
- Latest round: Series B (Mar 5, 2018)
- Investors on record: 7

## About

ViewPoint Therapeutics, founded in 2014 and based in San Francisco, US, specializes in developing innovative therapies for ocular diseases, focusing on optimizing drug delivery systems to improve patient outcomes.ViewPoint Therapeutics is engaged in the research and development of therapies aimed at treating ocular diseases. The company was founded in 2014 and is headquartered in San Francisco, California. In September 2022, ViewPoint was acquired by Visus Therapeutics, which will leverage ViewPoint’s extensive library of drug candidates for ocular delivery. The CEO of ViewPoint Therapeutics is Leah Makley.ViewPoint Therapeutics develops innovative drug candidates for treating ocular diseases, emphasizing advanced drug delivery mechanisms. Their research is geared towards creating therapies that enhance the effectiveness and reach of treatments specifically designed for eye-related conditions.ViewPoint Therapeutics has raised a total of USD 35.00 mn through funding rounds, with the latest being a Series B round led by TPG. The current estimated company valuation stands at USD 75.88 mn.Following its acquisition by Visus Therapeutics, ViewPoint Therapeutics is expected to further advance its pipeline of ocular drug candidates. The financial infusion from the acquisition will enable the development of new products targeting ocular conditions. Plans for expansion into additional therapeutic areas may also be explored in the coming years as the company aligns with Visus Therapeutics' broader strategy.

## Funding rounds

- Series B, Mar 5, 2018, $35M — TPG, Novo Holdings, Mission Bay Capital, University of Michigan (Ross School of Business), BVF Partners, Lagunita BioSciences
- Series A, Apr 14, 2016, $4M — Asset Management Ventures, Mission Bay Capital, University of Michigan (Ross School of Business), BVF Partners, Lagunita BioSciences

## Investors

- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series A
- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series A, Series B
- University of Michigan (Ross School of Business) (https://capitalatlas.ai/funds/university-of-michigan-ross-school-of-business) — Series A, Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A, Series B
- Lagunita BioSciences — Series A, Series B
- TPG (https://capitalatlas.ai/funds/tpg) — Series B
- Novo Holdings — Series B